Avior Wealth Management’s Relay Therapeutics RLAY Stock Holding History

Avior Wealth Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18	Closed	-$149	–	3418
2024 Q1	$149	Buy	+18	New	+$176	﹤0.01%	3004

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Avior Wealth Management's RLAY Position: Q2 2024 in Review

Avior Wealth Management sold out of Relay Therapeutics (RLAY) in Q2 2024, closing a stake of 18 shares — an estimated $149 sold.

Avior Wealth Management first reported a position in RLAY in Q1 2024 and held it in 1 quarter. The position peaked at $149 in Q1 2024. 178 funds tracked by Wall St. Rank hold RLAY as of Q2 2024.

Avior Wealth Management reported no remaining Relay Therapeutics position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 18 Relay Therapeutics shares in Q2 2024, an estimated $149.
Avior Wealth Management first reported a position in Relay Therapeutics in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Relay Therapeutics position peaked at $149 in Q1 2024.
178 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.